PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.92%
Negative revenue growth while AVGO stands at 0.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-9.52%
Negative gross profit growth while AVGO is at 0.51%. Joel Greenblatt would examine cost competitiveness or demand decline.
-17.63%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-17.63%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-4.84%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-2.13%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
No Data
No Data available this quarter, please select a different quarter.
-2.52%
Share reduction while AVGO is at 0.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.41%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
29.35%
Dividend growth above 1.5x AVGO's 0.14%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
101.67%
OCF growth above 1.5x AVGO's 7.23%. David Dodd would confirm a clear edge in underlying cash generation.
341.26%
FCF growth above 1.5x AVGO's 6.62%. David Dodd would verify if the firm’s strategic investments yield superior returns.
204.26%
10Y revenue/share CAGR under 50% of AVGO's 409.54%. Michael Burry would suspect a lasting competitive disadvantage.
111.21%
5Y revenue/share CAGR similar to AVGO's 122.61%. Walter Schloss might see both companies benefiting from the same mid-term trends.
120.70%
3Y revenue/share CAGR above 1.5x AVGO's 60.90%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
37.20%
10Y OCF/share CAGR under 50% of AVGO's 441.92%. Michael Burry would worry about a persistent underperformance in cash creation.
18.07%
Below 50% of AVGO's 73.80%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
39.81%
3Y OCF/share CAGR 1.25-1.5x AVGO's 34.25%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
2571.27%
Net income/share CAGR above 1.5x AVGO's 691.11% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
727.64%
5Y net income/share CAGR 1.25-1.5x AVGO's 651.30%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
129.87%
3Y net income/share CAGR above 1.5x AVGO's 66.58%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
187.22%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
4.23%
Below 50% of AVGO's 147.32%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
69.04%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
87.75%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
75.60%
Similar 5Y dividend/share CAGR to AVGO's 71.80%. Walter Schloss sees parallel philosophies in mid-term capital returns.
184.42%
3Y dividend/share CAGR above 1.5x AVGO's 38.29%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-15.08%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-3.62%
Inventory is declining while AVGO stands at 5.71%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-5.78%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-3.10%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-2.46%
Our R&D shrinks while AVGO invests at 19.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.39%
We cut SG&A while AVGO invests at 14.12%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.